Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2006

01.12.2006

Clinical Implications of Combined Portal Vein Resection as a Palliative Procedure in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Head Carcinoma

verfasst von: Kazuaki Shimada, MD, Tsuyoshi Sano, MD, Yoshihiro Sakamoto, MD, Tomoo Kosuge, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

The clinical implications of combined portal vein resections are controversial.

Methods

One-hundred and forty-nine consecutive patients underwent macroscopically curative pancreatectomies for pancreatic head carcinoma between January 1, 1996 and December 31, 2004. Portal vein resection was performed in 86 patients (58%). Data on surgical mortality, morbidity, perioperative outcome, pathological factors, initial recurrence site, and survival were retrospectively compared between the patients with and without portal vein resection.

Results

The incidence of postoperative pancreatic fistula was lower among patients who underwent portal vein resection. The median survival period was 14 months for the portal vein resection group and 35 months for the non-portal vein resection group, respectively. Combined portal vein resection was a significant predictor of poor survival using a multivariate analysis. Portal vein resection was strongly associated with larger tumor size, the degree of retropancreatic tissue invasion, the presence of extrapancreatic nerve plexus invasion, lymph node metastases, and positive cancer infiltration at the surgical margins.

Conclusions

Portal vein resection at the time of pancreaticoduodenectomy can be safely performed. However, most of patients requiring portal vein resection do not achieve a potentially curative resection or a favorable survival term. As a result, the aggressive application and the strict selection of portal vein resection might reduce the incidence of positive surgical margins, enabling long-term survival in patients who do not require portal vein resection.
Literatur
2.
Zurück zum Zitat Nitecki SS, Sarr MG, Colby TV, Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 1995; 221: 59–66PubMedCrossRef Nitecki SS, Sarr MG, Colby TV, Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 1995; 221: 59–66PubMedCrossRef
3.
Zurück zum Zitat Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992; 215: 231–236PubMedCrossRef Ishikawa O, Ohigashi H, Imaoka S, et al. Preoperative indications for extended pancreatectomy for locally advanced pancreas cancer involving the portal vein. Ann Surg 1992; 215: 231–236PubMedCrossRef
4.
Zurück zum Zitat Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167: 104–113PubMedCrossRef Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167: 104–113PubMedCrossRef
5.
Zurück zum Zitat Furukawa H, Kosuge T, Mukai K, et al. Helical computed tomography in the diagnosis of portal vein invasion by pancreatic head carcinoma. Arch Surg 1998; 133: 61–65PubMedCrossRef Furukawa H, Kosuge T, Mukai K, et al. Helical computed tomography in the diagnosis of portal vein invasion by pancreatic head carcinoma. Arch Surg 1998; 133: 61–65PubMedCrossRef
6.
Zurück zum Zitat Takahashi S, Ogata Y, Tsuzuki T. Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg 1994; 81: 1190–1193PubMed Takahashi S, Ogata Y, Tsuzuki T. Combined resection of the pancreas and portal vein for pancreatic cancer. Br J Surg 1994; 81: 1190–1193PubMed
7.
Zurück zum Zitat Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995; 117: 50–55PubMedCrossRef Nakao A, Harada A, Nonami T, Kaneko T, Inoue S, Takagi H. Clinical significance of portal invasion by pancreatic head carcinoma. Surgery 1995; 117: 50–55PubMedCrossRef
8.
Zurück zum Zitat Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996; 224: 342–349PubMedCrossRef Harrison LE, Klimstra DS, Brennan MF. Isolated portal vein involvement in pancreatic adenocarcinoma. A contraindication for resection? Ann Surg 1996; 224: 342–349PubMedCrossRef
9.
Zurück zum Zitat Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85: 611–617PubMedCrossRef Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head. Br J Surg 1998; 85: 611–617PubMedCrossRef
10.
Zurück zum Zitat Bachellier P, Nakano H, Oussoultzoglou E, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001; 182: 120–129PubMedCrossRef Bachellier P, Nakano H, Oussoultzoglou E, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile? Am J Surg 2001; 182: 120–129PubMedCrossRef
11.
Zurück zum Zitat Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002; 168: 707–12PubMedCrossRef Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002; 168: 707–12PubMedCrossRef
12.
Zurück zum Zitat Nakaghori T, Kinoshita T, Konishi M, et al. Survival benefits of portal vein resection for pancreatic cancer Am J Surg 2003;186: 149–153CrossRef Nakaghori T, Kinoshita T, Konishi M, et al. Survival benefits of portal vein resection for pancreatic cancer Am J Surg 2003;186: 149–153CrossRef
13.
Zurück zum Zitat Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Ann Surg 1996; 223: 154–162PubMedCrossRef Fuhrman GM, Leach SD, Staley CA, et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Ann Surg 1996; 223: 154–162PubMedCrossRef
14.
Zurück zum Zitat Tseng JF, Raut CP, Lee JE, et al. Pancreatoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8: 935–49PubMedCrossRef Tseng JF, Raut CP, Lee JE, et al. Pancreatoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8: 935–49PubMedCrossRef
15.
Zurück zum Zitat Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection? Am J Surg 1996; 171: 170–175PubMedCrossRef Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection? Am J Surg 1996; 171: 170–175PubMedCrossRef
16.
Zurück zum Zitat Launois B, Stasik C, Bardaxoglou E, et al. Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer? World J Surg 1999; 23: 926–929PubMedCrossRef Launois B, Stasik C, Bardaxoglou E, et al. Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer? World J Surg 1999; 23: 926–929PubMedCrossRef
17.
Zurück zum Zitat Geenen RC, Kate FJ, Wit LT, et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001; 129: 158–163PubMedCrossRef Geenen RC, Kate FJ, Wit LT, et al. Segmental resection and wedge excision of the portal or superior mesenteric vein during pancreatoduodenectomy. Surgery 2001; 129: 158–163PubMedCrossRef
18.
Zurück zum Zitat Yachida S, Fukushima N, Sakamoto M, Matsuno T, Kosuge T, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially respectable pancreatic cancer. Br J Surg 2002; 89: 573–578PubMedCrossRef Yachida S, Fukushima N, Sakamoto M, Matsuno T, Kosuge T, Hirohashi S. Implications of peritoneal washing cytology in patients with potentially respectable pancreatic cancer. Br J Surg 2002; 89: 573–578PubMedCrossRef
19.
Zurück zum Zitat Ozaki H, Kinoshita H, Kosuge T, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancteatol 2000; 27: 217–224CrossRef Ozaki H, Kinoshita H, Kosuge T, et al. Long-term survival after multimodality treatment for resectable pancreatic cancer. Int J Pancteatol 2000; 27: 217–224CrossRef
20.
Zurück zum Zitat Shimada K, Sano T, Sakamoto Y, Kosuge T. Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy. Hepatogastroenterology 2005; 52:1872–7 Shimada K, Sano T, Sakamoto Y, Kosuge T. Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy. Hepatogastroenterology 2005; 52:1872–7
21.
Zurück zum Zitat Japan Pancreas Society. (1996) Classification of pancreatic cancer, 1st Engl edn. Tokyo: Kanehara Japan Pancreas Society. (1996) Classification of pancreatic cancer, 1st Engl edn. Tokyo: Kanehara
22.
Zurück zum Zitat Sobin LH, Wittekind Ch. (2002) TNM Classification of Malignant tumors, 6th ed. New York, NY: JohnWiley & Sons Inc. Sobin LH, Wittekind Ch. (2002) TNM Classification of Malignant tumors, 6th ed. New York, NY: JohnWiley & Sons Inc.
23.
Zurück zum Zitat Hamanaka Y, Nishihama K, Hamasaki T, et al. Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Surgery 1996; 119: 281–287PubMedCrossRef Hamanaka Y, Nishihama K, Hamasaki T, et al. Pancreatic juice output after pancreatoduodenectomy in relation to pancreatic consistency, duct size, and leakage. Surgery 1996; 119: 281–287PubMedCrossRef
24.
Zurück zum Zitat Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208: 215–220PubMedCrossRef Ishikawa O, Ohhigashi H, Sasaki Y, et al. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988; 208: 215–220PubMedCrossRef
25.
Zurück zum Zitat Lϋttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B,Klöppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998; 433: 237–242PubMedCrossRef Lϋttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B,Klöppel G. The retroperitoneal resection margin and vessel involvement are important factors determining survival after pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas. Virchows Arch 1998; 433: 237–242PubMedCrossRef
26.
Zurück zum Zitat Nagai H, Koroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986; 204: 65–71PubMedCrossRef Nagai H, Koroda A, Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 1986; 204: 65–71PubMedCrossRef
27.
Zurück zum Zitat Ishikawa O, Ohigashi H, Sasaki Y, et al. Intraoperative cytodiagnosis for detecting a minute invasion of the portal vein during pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Am J Surg 1998; 175: 477–481PubMedCrossRef Ishikawa O, Ohigashi H, Sasaki Y, et al. Intraoperative cytodiagnosis for detecting a minute invasion of the portal vein during pancreaticoduodenectomy for adenocarcinoma of the pancreatic head. Am J Surg 1998; 175: 477–481PubMedCrossRef
28.
Zurück zum Zitat Nakao A, Kaneko T. Intravascular ultrasonography for assessment of portal vein invasion by pancreatic carcinoma. World J Surg 1999; 23:892–5PubMedCrossRef Nakao A, Kaneko T. Intravascular ultrasonography for assessment of portal vein invasion by pancreatic carcinoma. World J Surg 1999; 23:892–5PubMedCrossRef
29.
Zurück zum Zitat Yamaue H, Tani M, Onishi H, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002; 25: 366–372PubMedCrossRef Yamaue H, Tani M, Onishi H, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas 2002; 25: 366–372PubMedCrossRef
Metadaten
Titel
Clinical Implications of Combined Portal Vein Resection as a Palliative Procedure in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Head Carcinoma
verfasst von
Kazuaki Shimada, MD
Tsuyoshi Sano, MD
Yoshihiro Sakamoto, MD
Tomoo Kosuge, MD
Publikationsdatum
01.12.2006
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2006
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-006-9143-4

Weitere Artikel der Ausgabe 12/2006

Annals of Surgical Oncology 12/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.